U.S. markets closed
  • S&P 500

    3,269.96
    -40.15 (-1.21%)
     
  • Dow 30

    26,501.60
    -157.51 (-0.59%)
     
  • Nasdaq

    10,911.59
    -274.00 (-2.45%)
     
  • Russell 2000

    1,538.48
    -23.10 (-1.48%)
     
  • Crude Oil

    35.72
    -0.45 (-1.24%)
     
  • Gold

    1,878.80
    +10.80 (+0.58%)
     
  • Silver

    23.72
    +0.35 (+1.52%)
     
  • EUR/USD

    1.1641
    -0.0037 (-0.31%)
     
  • 10-Yr Bond

    0.8600
    +0.0250 (+2.99%)
     
  • GBP/USD

    1.2953
    +0.0030 (+0.23%)
     
  • USD/JPY

    104.6350
    +0.0250 (+0.02%)
     
  • BTC-USD

    13,768.30
    +49.50 (+0.36%)
     
  • CMC Crypto 200

    265.42
    +1.78 (+0.68%)
     
  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Illumina Analysts Question Grail Deal's Commercial Opportunity, Hefty Price Tag

Shanthi Rexaline
·3 mins read

Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. 

The Illumina Analysts: Baird analyst Catherine Ramsey Schulte maintained a Neutral rating on Illumina shares and lowered the price target from $335 to $281.

JPMorgan analyst Tycho Peterson downgraded Illumina shares from Overweight to Neutral and reduced the price target from $390 to $280.

Wells Fargo Securities analyst Dan Leonard maintained an Underweight rating and took the price target from $290 down to $250.

Baird Cautious On Grail Deal: Although the deal presents a large market opportunity, the reimbursement landscape remains uncertain, Ramsey Schulte said in a note.

Given the hefty price tag, the analyst said she is cautious on the patience that will be required in the years ahead before any potential meaningful adoption can be seen.

Baird said it is adding Grail to its model, assuming a December 2021 close, with $3.50 of EPS dilution in 2022 and what it views as an optimistic ramp scenario given the uncertain reimbursement landscape and fragmented market.

See also: The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix

JPMorgan Finds It Hard To Get Excited: The deal will allow Illumina to participate in the early cancer detection market, estimated at $60 billion by 2023, Peterson said.

At launch, Grail's Galleri cancer screening test will have an initial addressable market of 52 million lives prior to reimbursement, with test ASPs estimated to start at $1,200, the analyst said. 

The deal has uncertainty around the pace of market penetration and revenue generation, a lack of operational synergies, significant near-term dilution and potential distraction and dilution from the core business recovery next year, he said. 

Even without the deal, Illumina was already positioned to participate in Grail's ramp through its 14.5% stake in the company, HSD royalties, supply arrangement and more, Peterson said. 

Grail's Test Opportunity Unconvincing, Wells Fargo Says: Wells Fargo's bearish stance on Illumina is based on the firm's view that Street sales and earnings forecasts have more potential downside risk than upside potential, Leonard said in a note. 

Illumina's proposed deal to buy Grail carries much higher-than-expected earnings dilution, the analyst said, adding that he doesn't share the company's conviction in the commercial opportunity for Grail's cancer screening test.

ILMN Price Action: After declining 8.6% Monday, Illumina shares were down another 0.67% at $268.33 at the time of publication Tuesday. 

Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

Latest Ratings for ILMN

Date

Firm

Action

From

To

Sep 2020

Canaccord Genuity

Maintains

Hold

Sep 2020

Baird

Maintains

Neutral

Sep 2020

UBS

Downgrades

Buy

Neutral

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.